Pain Therapeutics, Inc. develops proprietary drugs that offer significant improvements to patients and healthcare professionals. The company generally focuses its drug development efforts on disorders of the nervous system, such as chronic pain. The company’s expertise consists of developing new drug candidates and guiding these through various regulatory and development pathways in preparation for their eventual commercialization. Its primary drug candidate is called REMOXY (oxycodone capsules CII). REMOXY is a proprietary, abuse-deterrent, oral formulation of oxycodone (CII). The company developed REMOXY to make oxycodone difficult to abuse yet provide 12 hours of steady pain relief when used appropriately by patients. The company owns exclusive, worldwide rights to REMOXY. REMOXY is a proprietary, abuse-deterrent, oral formulation of oxycodone (CII). The company developed REMOXY to make oxycodone difficult to abuse yet provide 12 hours of steady pain relief when used appropriately by patients. REMOXY is intended to meet the needs of healthcare professionals who appropriately prescribe opioid drugs. FENROCK is a trade name for the company’s proprietary, abuse-deterrent pain patch. FENROCK’s active drug ingredient is fentanyl (CII), a highly addictive opioid drug that is up to 50 times more powerful than morphine. FENROCK is an early-stage drug candidate. The company is working with outside collaborators on the development of a final formulation of FENROCK. It owns exclusive, worldwide rights to FENROCK. PTI-125, an oral drug, was designed in-house and characterized by outside collaborators. The company owns exclusive, worldwide rights to PTI-125. Strategy The key elements of the company’s strategy are to focus on clinical development stage products; retain significant rights to its drugs; outsource key functions; and pursue in-licensing or acquisition opportunities. Intellectual Property The company owns or licenses various U.S. and foreign patents, patent applications and rights to patents covering its products and technology. Its patents and the patents it licenses from third parties include the following issued U.S. Patents: 8,168,217; 8,153,152; 8,147,870; 8,133,507; 8,354,124; 8,415,401; 8,420,120; 8,974,821; 8,945,614; 8,951,556; and 9,233,160. The company’s issued U.S. patent for REMOXY with the longest patent term extends to 2031. Outside the U.S., its granted patent with the longest patent term for REMOXY extends to 2028. It uses a process to manufacture REMOXY. The company also protects as trade secrets the significant pharmaceutical know-how and detailed knowledge of a complex supply chain to manufacture REMOXY. REMOXY and FENROCK are trademarks of the company. Agreements The company has an exclusive, worldwide development and license agreement with Durect Corporation to use a patented technology that forms the basis for certain drug candidates, including REMOXY. History Pain Therapeutics, Inc. was founded in 1998. The company was incorporated in Delaware in 1998.
pain therapeutics inc (PTIE:NASDAQ GS)
7801 North Capital of Texas Highway
Austin, TX 78731
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for PTIE.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact PAIN THERAPEUTICS INC, please visit www.paintrials.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.